IDH2 and angioimmunoblastic T-cell lymphoma: Nevertheless, since IDH2R140Q is the most frequent mutation found in AML and IDH2 mutations were also found in angioimmunoblastic T cell lymphoma (20, 197), enasidenib was developed as inhibitor of mutant IDH2, inducing molecular remissions (159).